<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00807690</url>
  </required_header>
  <id_info>
    <org_study_id>182-04066</org_study_id>
    <nct_id>NCT00807690</nct_id>
  </id_info>
  <brief_title>Vitiligo Treated With TL01 Combined With Tacrolimus Ointment Versus Placebo</brief_title>
  <official_title>Treatment of Vitiligo With Narrowband UVB (TL01) Combined With Tacrolimus (0.1%) Versus Placebo Ointment, a Randomized Right/Left Double Blind Comparative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <brief_summary>
    <textblock>
      BACKGROUND Vitiligo is a common, often distressing condition. Many of the patients do not&#xD;
      achieve sufficient effect from what is regarded as the treatment of choice at present, narrow&#xD;
      band(NB)UVB(Tl01). There are reports on some patients partly successfully treated with&#xD;
      Tacrolimus ointment.&#xD;
&#xD;
      AIM OF THE STUDY We want to study whether Tacrolimus ointment may give an additive effect on&#xD;
      symmetric vitiligo in combination with NB-UVB.&#xD;
&#xD;
      METHODS This is a double blind left/right comparative study with 6 months treatment time.&#xD;
      Patients are treated with whole body NB-UVB x 2 or x 3 weekly, in addition to Tacrolimus&#xD;
      ointment versus placebo every night on affected half body sites. To measure effects we use&#xD;
      photodocumentation in addition to morphometric registration of symmetric target lesions every&#xD;
      6 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>Vitiligo</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus ointment</intervention_name>
    <description>Tacrolimus ointment 0.1%every night for at least 3 months, half body side</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged at least 18 years with a stable, symmetric vitiligo&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with segmental vitiligo, aged &lt; 18 years, known hypersensitivity to&#xD;
             Tacrolimus, pregnant or breastfeeding women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eli Johanne Nordal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rikshospitalet HF, Dept. of Dermatology</affiliation>
  </overall_official>
  <verification_date>December 2008</verification_date>
  <study_first_submitted>December 11, 2008</study_first_submitted>
  <study_first_submitted_qc>December 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2008</study_first_posted>
  <last_update_submitted>December 11, 2008</last_update_submitted>
  <last_update_submitted_qc>December 11, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2008</last_update_posted>
  <responsible_party>
    <name_title>Eli Johanne Nordal/senior consultant</name_title>
    <organization>Rikshospitalet HF</organization>
  </responsible_party>
  <keyword>vitiligo</keyword>
  <keyword>tacrolimus ointment 0.1%</keyword>
  <keyword>narrowband UVB (TL01)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitiligo</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

